Link to Enanta Home Page
  • About
    • About Us
    • Management Team
    • Board of Directors
    • Timeline
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Immunology
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
    • Financials
    • Corporate Responsibility
    • Investor Resources
  • Contact Us

About

  • About
    • About Us
    • Management Team
    • Board of Directors
    • Timeline
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Immunology
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Quartlery Results
      • Annual Reports
      • SEC Filings
    • Corporate Responsibility
      • Overview
      • Environmental
      • Social
      • Governance
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • RSS Feed
  • Contact Us

2018

Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus

enanta logo

©2024 Enanta Pharmaceuticals, Inc.

ENANTA PHARMACEUTICALS and accompanying logos are trademarks or registered trademarks of Enanta Pharmaceuticals, Inc.

Explore

  • About
  • Pipeline
  • Science
  • Patients
  • Careers
  • Collaborations
  • Investors
  • Contact Us

Contact

Enanta Pharmaceuticals, Inc.
Headquarters
4 Kingsbury Avenue
Watertown, MA 02472

(617) 607-0800
info@enanta.com

Legal

  • Privacy Policy
  • Terms of Use
twitter icon linkedin icon
MENU
  • About
    • About Us
    • Management Team
    • Board of Directors
    • Timeline
  • Pipeline
    • Overview
    • Hepatitis C Virus
    • Hepatitis B Virus
    • Respiratory Syncytial Virus
    • SARS-CoV-2
    • Immunology
  • Science
    • Overview
    • Publications
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
    • Resources
  • Careers
    • Join Us
    • Culture
    • Core Values
    • Testimonials
    • Benefits
  • Collaborations
    • Partnering
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials
      • Quartlery Results
      • Annual Reports
      • SEC Filings
    • Corporate Responsibility
      • Overview
      • Environmental
      • Social
      • Governance
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • RSS Feed
  • Contact Us